Targeting LCE1E: A Potential Drug for Neurodegenerative and Cancer Diseases

Target Name: LCE1E

NCBI ID: G353135

LCE1E

Targeting LCE1E: A Potential Drug for Neurodegenerative and Cancer Diseases

LCE1E (LCE1E_HUMAN), a protein located in the endoplasmic reticulum (ER), has been identified as a potential drug target and biomarker for various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. its one of the most interesting protein in the human body that can be targeted by small molecules.

LCE1E is a transmembrane protein that plays a crucial role in the regulation of endoplasmic reticulum (ER) function. It is one of the most well-known proteins that is expressed in the ER and is involved in the sorting of various proteins into the ER. LCE1E is composed of 116 amino acids and has a calculated molecular weight of 13.9 kDa.

Recent studies have suggested that LCE1E may be involved in the development and progression of various diseases. For example, LCE1E has been shown to be overexpressed in various neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, LCE1E has also been shown to be overexpressed in various cancer types, such as lung, breast, and ovarian cancer.

Furthermore, LCE1E has also been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway. TGF-β is a well-known protein that is involved in the regulation of cell growth, differentiation, and survival. LCE1E has been shown to be involved in the regulation of TGF-β signaling by interacting with the protein Smad2.

Smad2 is a key regulator of TGF-β signaling and is thought to play a role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation. LCE1E has been shown to interact with Smad2 and to modulate the activity of Smad2. This suggests that LCE1E may be a useful target for small molecules that can modulate TGF-β signaling and potentially have therapeutic benefits for a variety of diseases.

In addition to its role in TGF-β signaling, LCE1E has also been shown to play a role in the regulation of cellular adhesion. Adhesion is a process by which cells stick together and form tissues. LCE1E is involved in the regulation of cell-cell adhesion by interacting with the protein Zeb1.

Zeb1 is a protein that is involved in the regulation of cell-cell adhesion and has been shown to play a role in various diseases, including cancer. LCE1E has been shown to interact with Zeb1 and to modulate its activity. This suggests that LCE1E may be a useful target for small molecules that can modulate cell-cell adhesion and potentially have therapeutic benefits for a variety of diseases.

Finally, LCE1E has also been shown to play a role in the regulation of protein synthesis and may be a potential drug target for diseases associated with protein synthesis. Proteins are the building blocks of life and are involved in many cellular processes. LCE1E is involved in the regulation of protein synthesis by interacting with the protein FADD.

FADD is a protein that is involved in the regulation of protein synthesis and has been shown to play a role in various diseases, including cancer. LCE1E has been shown to interact with FADD and to modulate its activity. This suggests that LCE1E may be a useful target for small molecules that can modulate protein synthesis and potentially have therapeutic benefits for a variety of diseases.

In conclusion, LCE1E is a protein that is involved in the regulation of end

Protein Name: Late Cornified Envelope 1E

Functions: Precursors of the cornified envelope of the stratum corneum

The "LCE1E Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LCE1E comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets